somatuline autogel (lanreotide as acetate) 60mg solution for injection prefilled syringe
ipsen pty ltd - lanreotide acetate, quantity: 77.9 mg (equivalent: lanreotide, qty 65.4 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
somatuline la lanreotide 30mg (as acetate) powder for injection vial with diluent ampoule
ipsen pty ltd - lanreotide acetate -
mytolac lanreotide (as acetate) 60 mg solution for injection pre-filled syringe
amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 66.67 mg (equivalent: lanreotide, qty 60 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac lanreotide (as acetate) 120 mg solution for injection pre-filled syringe
amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 133.33 mg (equivalent: lanreotide, qty 120 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac lanreotide (as acetate) 90 mg solution for injection pre-filled syringe
amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 100 mg (equivalent: lanreotide, qty 90 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
lanreotide 60mg/0.5ml solution for injection pre-filled syringes
advanz pharma - lanreotide acetate - solution for injection - 120mg/1ml
lanreotide 90mg/0.5ml solution for injection pre-filled syringes
advanz pharma - lanreotide acetate - solution for injection - 180mg/1ml
lanreotide 120mg/0.5ml solution for injection pre-filled syringes
advanz pharma - lanreotide acetate - solution for injection - 240mg/1ml
lanreotide 60mg/0.5ml solution for injection pre-filled syringes
ipsen ltd - lanreotide acetate - solution for injection - 120mg/1ml
lanreotide 90mg/0.5ml solution for injection pre-filled syringes
ipsen ltd - lanreotide acetate - solution for injection - 180mg/1ml